Dr. Kristen Spencer, MD
Claim this profileRutgers Cancer Institute of New Jersey
Studies Cancer
Studies Pancreatic Cancer
14 reported clinical trials
46 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
KRAS positive
2Pancreatic Cancer
Stage IV
Stage III
KRAS positive
Affiliated Hospitals
Clinical Trials Kristen Spencer, MD is currently running
CAR T-Cell Preparation
for Cancer
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.
Recruiting1 award N/A3 criteria
CA-4948 + Chemotherapy
for Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3) that signal cells to multiply. This may help keep cancer cells from growing. The usual approach for patients with pancreatic ductal adenocarcinoma is treatment with chemotherapy drugs gemcitabine and nab-paclitaxel. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving CA-4948 in combination with gemcitabine and nab-paclitaxel may shrink or stabilize metastatic or unresectable pancreatic ductal adenocarcinoma.
Recruiting1 award Phase 120 criteria
More about Kristen Spencer, MD
Clinical Trial Related3 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Kristen Spencer, MD has experience with
- Atezolizumab
- Panitumumab
- Sotorasib
- Nab-paclitaxel
- Nivolumab
- Olaparib
Breakdown of trials Kristen Spencer, MD has run
Cancer
Pancreatic Cancer
Solid Tumors
Bile Duct Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kristen Spencer, MD specialize in?
Kristen Spencer, MD focuses on Cancer and Pancreatic Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Kristen Spencer, MD currently recruiting for clinical trials?
Yes, Kristen Spencer, MD is currently recruiting for 4 clinical trials in New Brunswick New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Kristen Spencer, MD has studied deeply?
Yes, Kristen Spencer, MD has studied treatments such as Atezolizumab, Panitumumab, Sotorasib.
What is the best way to schedule an appointment with Kristen Spencer, MD?
Apply for one of the trials that Kristen Spencer, MD is conducting.
What is the office address of Kristen Spencer, MD?
The office of Kristen Spencer, MD is located at: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States. This is the address for their practice at the Rutgers Cancer Institute of New Jersey.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.